Latest From Polaris Group
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Response rate data supports yet another supplemental approval for Opdivo in an underserved tumor type that is becoming more competitive.
The treatment of liver cancer will have a makeover in coming months, with several products including Bristol’s Opdivo nearing the market for a disease that is often diagnosed late and where previously there have been few meaningful advances in therapy for many years. Two recently published reports from Datamonitor Healthcare have reviewed the disease and the R&D pipeline for the condition.
In its second cancer deal in two months, Incyte licenses a first-in-class asset expected to offer potential cancer immunotherapy synergy with IDO1 and checkpoint inhibition.
- Therapeutic Areas
- Infectious & Viral Diseases
- Metabolic Disorders
- Polaris Pharmaceuticals Inc.
- North America
- Parent & Subsidiaries
- Polaris Group
- Senior Management
Robert E Hoffman, CFO
John Bomalaski, MD, VP, Med. Aff.
- Contact Info
Phone: (858) 452-6688
6370 Nancy Ridge Dr.
San Diego, CA 92121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.